METHOTREXATE WITHDRAWAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVE LOW DISEASE ACTIVITY WITH TOFACITINIB MODIFIED-RELEASE 11 MG ONCE DAILY plus METHOTREXATE: A RANDOMISED NON-INFERIORITY PHASE 3B/4 STUDY

被引：3

作者：

Cohen, Stanley B. ^{[1
]}

Pope, Janet ^{[2
]}

Haraoui, Boulos ^{[3
]}

Irazoque-Palazuelos, Fedra ^{[4
]}

Korkosz, Mariusz ^{[5
]}

Diehl, Annette ^{[6
]}

Luis Rivas, Jose ^{[7
]}

Lukic, Tatjana ^{[8
]}

Liu, Shixue ^{[9
]}

Stockert, Lori ^{[6
]}

Iikuni, Noriko ^{[8
]}

Keystone, Edward ^{[10
]}

机构：

[1] Metroplex Clin Res Ctr, Dallas, TX USA

[2] Western Univ, London, ON, Canada

[3] Inst Rhumatol Montreal, Montreal, PQ, Canada

[4] Ctr Invest & Tratamiento Rheumatol, Mexico City, DF, Mexico

[5] Jagiellonian Univ, Coll Med, Krakow, Poland

[6] Pfizer Inc, Collegeville, PA USA

[7] Pfizer SLU, Madrid, Spain

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Shanghai, Peoples R China

[10] Univ Toronto, Toronto, ON, Canada

来源：

关键词：

D O I：

10.1136/annrheumdis-2019-eular.8657

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB0004

引用

页码：260 / 261

页数：2

共 1 条